Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol for Vessel Wall Effects in Nephropathy
NCT02372695Phase 4Terminated
- Start
- Jul 2012
- Primary completion
- May 2013
- Modality
- Orthosteric Ligands
01
Overview
Phase 4, randomised, open-label trial of paricalcitol in chronic kidney disease (CKD) (2 arms). Primary endpoint: Prevention on vessels progression based on paricalcitol intake at 1 year. Started Jul 2012; status: terminated.
02
Drugs
paricalcitol
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02372695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02372695.